Role of epidemiology in the EU policy formulation of chemicals

Abstract Over the past 50 years, the European Union has built a robust legal framework for managing chemicals. This framework balances the benefits of using chemicals for societal well-being and economic prosperity with the need to protect human health and the environment from potential risks. As part of the EU’s Zero Pollution ambition in the context of the Green Deal, the European Commission adopted in 2020 the Chemicals Strategy for Sustainability, with the aim to better protect human health and the environment from harmful chemicals, while boosting innovation by promoting the use of safer and more sustainable chemicals. Assessing quantitative health impacts within the EC Better Regulation guidance typically involves indicators measuring the environmental burden of disease (EBD), providing a useful mean for legislators to evaluate the benefits of policy actions both in terms of health gains and cost. While such analyses are common in air pollution studies, challenges arise in the chemical legislation area, particularly in non-occupational settings, where the population is exposed to low concentrations of many chemicals through multiple exposure routes. In such contexts, the intrinsic complexities linked to exposure characterization and to the assessment of causality between the exposure and the health outcome may hinder the estimation of benefits of legislative actions. Debates may arise regarding the reliability of the underlying epidemiological studies, making challenging for policymakers to ascertain the robustness and generalizability of the findings of such analyses. Our work provides a summary and analysis of recent case studies in the context of chemicals. We focus on how epidemiological evidence was used in conducting EBD analyses in supporting better formulation of EU polices of chemicals. Speakers/Panelists Marleen Bekker Wageningen University & Research, Wageningen, Netherlands